M
Mary Motyl
Researcher at Merck & Co.
Publications - 106
Citations - 4437
Mary Motyl is an academic researcher from Merck & Co.. The author has contributed to research in topics: Imipenem & Pseudomonas aeruginosa. The author has an hindex of 28, co-authored 85 publications receiving 3627 citations.
Papers
More filters
Journal ArticleDOI
Platensimycin is a selective FabF inhibitor with potent antibiotic properties
Jun Wang,Stephen M. Soisson,Katherine Young,Wesley L. Shoop,Wesley L. Shoop,Srinivas Kodali,Andrew Galgoci,Ronald E. Painter,Gopalakrishnan Parthasarathy,Yui S. Tang,Richard D. Cummings,Sookhee Ha,Karen Dorso,Mary Motyl,Hiranthi Jayasuriya,John G. Ondeyka,Kithsiri Herath,Chaowei Zhang,Lorraine D. Hernandez,John J. Allocco,Angela Basilio,José R. Tormo,Olga Genilloud,Francisca Vicente,Fernando Pelaez,Lawrence F. Colwell,Sang Ho Lee,B.F. Michael,Thomas J. Felcetto,Charles Gill,Lynn L. Silver,Lynn L. Silver,Jeffery D. Hermes,Ken Bartizal,John F. Barrett,Dennis M. Schmatz,Joseph W. Becker,Doris F. Cully,Sheo B. Singh +38 more
TL;DR: Platensimycin demonstrates strong, broad-spectrum Gram-positive antibacterial activity by selectively inhibiting cellular lipid biosynthesis through the selective targeting of β-ketoacyl-(acyl-carrier-protein (ACP) in the synthetic pathway of fatty acids.
Journal ArticleDOI
Discovery of platencin, a dual FabF and FabH inhibitor with in vivo antibiotic properties.
Jun Wang,Srinivas Kodali,Sang Ho Lee,Andrew Galgoci,Ronald E. Painter,Karen Dorso,Fred Racine,Mary Motyl,Lorraine D. Hernandez,Elizabeth Tinney,Steven L. Colletti,Kithsiri Herath,Richard D. Cummings,Oscar Salazar,Ignacio González,Angela Basilio,Francisca Vicente,Olga Genilloud,Fernando Pelaez,Hiranthi Jayasuriya,Katherine Young,Doris F. Cully,Sheo B. Singh +22 more
TL;DR: Platencin shows potent in vivo efficacy without any observed toxicity, emphasizing the fact that more antibiotics with novel structures and new modes of action can be discovered by using this antisense differential sensitivity whole-cell screening paradigm.
Journal ArticleDOI
Clinical breakpoints for the echinocandins and Candida revisited: Integration of molecular, clinical, and microbiological data to arrive at species-specific interpretive criteria
M. A. Pfaller,Daniel J. Diekema,David R. Andes,Maiken Cavling Arendrup,S. D. Brown,Shawn R. Lockhart,Mary Motyl,David S. Perlin +7 more
TL;DR: New, species-specific CBPs for Candida and the echinocandins are more sensitive to detect emerging resistance associated with fks mutations, and better able to predict risk for clinical failure.
Journal ArticleDOI
Interlaboratory Comparison of Results of Susceptibility Testing with Caspofungin against Candida and Aspergillus Species
Frank C. Odds,Mary Motyl,Roberto Andrade,Jacques Bille,Emilia Cantón,Manuel Cuenca-Estrella,Amanda Denise Davidson,Christian Durussel,David Ellis,Elyse Foraker,Annette W. Fothergill,Mahmoud A. Ghannoum,Robert A. Giacobbe,Miguel Gobernado,Rosemary Handke,Michel Laverdière,Wendy Lee-Yang,William G. Merz,Luis Ostrosky-Zeichner,Javier Pemán,Sophia Perea,John R. Perfect,Michael A. Pfaller,Laurie A. Proia,John H. Rex,John H. Rex,Michael G. Rinaldi,Juan L. Rodriguez-Tudela,Wiley A. Schell,Christine E. Shields,Deanna A. Sutton,Paul E. Verweij,David W. Warnock +32 more
TL;DR: The minimal effective concentration end point, defined as the lowest caspofungin concentration yielding conspicuously aberrant hyphal growth, gave excellent reproducibility for data from 14 of the 17 participating laboratories, and the best interlaboratory separation of Candida isolates of known high and low susceptibility to casp ofungin.
Journal ArticleDOI
Global Escherichia coli Sequence Type 131 Clade with blaCTX-M-27 Gene.
Yasufumi Matsumura,Johann D. D. Pitout,Ryota Gomi,Tomonari Matsuda,Taro Noguchi,Masaki Yamamoto,Gisele Peirano,Rebekah DeVinney,Patricia A. Bradford,Mary Motyl,Michio Tanaka,Miki Nagao,Shunji Takakura,Satoshi Ichiyama +13 more
TL;DR: Increased extended-spectrum β-lactamase–producing E. coli in Japan resulted mainly from a clade containing this gene.